Search

748 Result(s)
Sort by

Lothar Halmer

Lothar Halmer

Dr. Lothar Halmer is Chief Quality Officer and leads the Global Quality Organization in providing quality products for our patients every day.
Boehringer Ingelheim Social Engagements

Boehringer Ingelheim Social Engagements

Boehringer Ingelheim Social Engagements Contributes to company commitment to impact 50 million people in vulnerable communities by 2030 through supporting social entrepreneurs and innovative solutions
Boehringer Ingelheim becomes member of IPC

Boehringer Ingelheim becomes member of IPC

Boehringer Ingelheim becomes member of IPC Boehringer Ingelheim is proud to join the International Poultry Council thus reaffirming its strong long-term commitment to shaping the future of poultry health. The International Poultry Council represents a uni
Vienna

Vienna

Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
History video

History video

Learn more about the history of the innovative pharmaceutical company Boehringer Ingelheim
Fight against COVID-19 pandemic

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Soaring to save lives

Soaring to save lives

Tackling health disparities through drone delivery of vaccines animals and livestock living in underserved communities
Rethinking mental health care

Rethinking mental health care

Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Focus on Alliance Management

Focus on Alliance Management

Stefan Walke, Global Head of Alliance Management, shares his perspectives on Alliance Management and its contribution to the development of successful long-term partnerships.
Micardis®

Micardis®

Treatment of hypertension. For the reduction of the risk of myocardial infarction (heart attack), stroke or death from cardiovascular (CV) causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take A